We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$191M
1-Year Est. Return
102.42%
This Fund
S&P 500
This Quarter
Est. Return
-0.95%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$41.5M
(+35%)
Cap. Flow
+$58M
Cap. Flow
% of AUM
36.57%
Top 10 Holdings %
Top 10 Hldgs %
58.29%
Holding
42
New
22
Increased
6
Reduced
6
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$6.15M |
| 2 |
Corcept Therapeutics
CORT
|
+$5.53M |
| 3 |
Delcath Systems
DCTH
|
+$5.24M |
| 4 |
Vor Biopharma
VOR
|
+$4.44M |
| 5 |
Orchestra BioMed
OBIO
|
+$3.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$3.5M |
| 2 |
Viridian Therapeutics
VRDN
|
+$2.15M |
| 3 |
Regenxbio
RGNX
|
+$1.68M |
| 4 |
IVA
Inventiva
IVA
|
+$1.68M |
| 5 |
Oculis Holding
OCS
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.98% |
| 2 | Energy | 19.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ovid Therapeutics
OVID
$547M
| $2.04M | 1.28% |
+921,457
| New | +$1.65M |
|
27
Palisade Bio
PALI
$349M
| $2M | 1.26% |
+1,115,000
| New | +$2.03M |
|
|
KLRS
28
Kalaris Therapeutics
KLRS
$95.9M
| $1.72M | 1.08% |
295,771
+253,718
| +603% | +$2.25M |
|
29
uniQure
QURE
$3.38B
| $1.71M | 1.08% |
+104,772
| New | +$2.12M |
|
|
LONA
30
LeonaBio Inc
LONA
$74.8M
| $1.5M | 0.94% |
149,279
| – | – |
|
31
Nuvation Bio
NUVB
$2.34B
| $1.41M | 0.89% |
+329,296
| New | +$1.83M |
|
|
MAZE
32
Maze Therapeutics
MAZE
$1.52B
| $1.31M | 0.82% |
+43,798
| New | +$1.93M |
|
|
EVMN
33
Evommune Inc
EVMN
$480M
| $1.28M | 0.81% |
+55,664
| New | +$1.26M |
|
34
Corvus Pharmaceuticals
CRVS
$1.19B
| $1.25M | 0.79% |
+85,791
| New | +$1.37M |
|
35
Aldeyra Therapeutics
ALDX
$89.9M
| $1.23M | 0.78% |
+730,606
| New | +$3.2M |
|
|
ARTV
36
Artiva Biotherapeutics
ARTV
$542M
| $950K | 0.6% |
+146,369
| New | +$724K |
|
|
CNTB
37
Connect Biopharma Holdings
CNTB
$140M
| $554K | 0.35% |
+209,493
| New | +$546K |
|
|
MSLE
38
Satellos Bioscience
MSLE
$184M
| $57.1K | 0.04% |
+10,145
| New | +$99.7K |
|
|
39
Nektar Therapeutics
NKTR
$2.48B
| – | – |
-82,822
| Closed | -$3.5M |
|
|
40
Regenxbio
RGNX
$638M
| – | – |
-116,896
| Closed | -$1.68M |
|
|
LENZ
41
LENZ Therapeutics
LENZ
$161M
| – | – |
-59,085
| Closed | -$945K |
|
|
AARD
42
Aardvark Therapeutics
AARD
$127M
| – | – |
-46,408
| Closed | -$609K |
|
Similar funds
CFG
MWM
ALWM
PFA
LKWM
NWM
AA
MCA
Propel Bio Management's Q1 2026 Portfolio in Review
As of Q1 2026, Propel Bio Management held 42 positions worth $159M, up 35% from $117M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Propel Bio Management deployed $58M of net new capital in Q1 2026, opening 22 new positions and adding to 6 existing holdings. Its largest new stake was Upstream Bio Inc: 341,779 shares worth $3.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Energy.
On the sell side, the largest reduction was Viridian Therapeutics, an estimated $2.15M trimmed.
- Propel Bio Management's largest Q1 2026 buy was Upstream Bio Inc: 341,779 shares worth $3.1M.
- Propel Bio Management added most to Delcath Systems in Q1 2026, an estimated $5.24M increase.
- Propel Bio Management's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $2.15M.
- Propel Bio Management fully exited Nektar Therapeutics in Q1 2026, selling an estimated $3.5M.
- Propel Bio Management's ten largest holdings make up 58% of its $159M portfolio in Q1 2026.
- Propel Bio Management opened 22 new positions and closed 4 in Q1 2026.
- Propel Bio Management's portfolio value rose 35% quarter-over-quarter to $159M.
Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.